Rayno Life Science Portfolio Updates-AMRN GNMK TDOC ; XBI is up 30% YTD…Update-12/17
Update-12/17. Amarin (AMRN)- A Sell on the News? AMRN stock tanked another 6.7% today on last weekend's news of the FDA approval of VASCEPA. This is what happens with momentum stocks with a well know story.The stock moved from the $25 level at Friday's close to $21.34 today on ridiculous volume...
Two Early Stage Biopharma Deals Focus on Oncology Assets…ARQL THOR…Update-1
Update-1 ...12/12/19...China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early Stage Pipeline Deals Diversify...
Biotech Scoreboard-November: Gene Therapy Stocks Gain Momentum…Update-2– BOLD
Update-2 ...12/3...Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid caps were green. RNAi platform...
Rayno BioBeat #3: Sentiment Shift Boosts Biotech and Healthcare Stocks Despite Political Undertow…Update-1 “green screen”
Update-1 11/25/19... Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We hold many winners today: ALNY,...
Healthcare Stocks Breakout and Biotech Stocks Rally Off the Bottom…Update-3 ALNY AMRN
Update-3 10/20...China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on 10/18 RNAi area heating up on...